Treatment options in metastatic renal cell carcinoma: Focus on mTOR inhibitors

Clinical Medicine Insights: Oncology

Volumn 4, Issue , 2010, Pages 43-53

  Pal, Sumanta Kumar ^a   Figlin, Robert A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Metastatic renal cell carcinoma; Mrcc; Mtor inhibitors

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; IMATINIB; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERIFOSINE; PLACEBO; PROTEIN KINASE B INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB;

ABSENCE OF SIDE EFFECTS; ACNE; ADVANCED CANCER; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLASSIFICATION ALGORITHM; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLIOBLASTOMA; GLIOMA; GRAPEFRUIT JUICE; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INTRACARDIAC THROMBOSIS; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG EMBOLISM; MELANOMA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTIC SYNDROME; NEUTROPHIL COUNT; NONHUMAN; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 78649358418     PISSN: None     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/cmo.s1590     Document Type: Review

References (76)

1. Fyfe G, Fisher R, Rosenberg S, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
2. Interferon-[alpha] and survival in metastatic renal carcinoma: early results of a randomised controlled trial. The Lancet. 1999;353:14-17.
3. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. J Clin Oncol. 2002;20:289-296.
4. Escudier B, Bellmunt J, Negrier S, et al. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. J Clin Oncol: JCO.2009.26.7849.
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med. 2007;356:125-134.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009;27:3584-3590.
7. Rini BI, Halabi S, Rosenberg JE, et al. Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206. J Clin Oncol: JCO.2009.26.5561.
8. Sternberg CN, Szczylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2009;27:5021.
9. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med. 2007;356: 2271-2281.
11. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells. J Biol Chem. 1995;270:815-822.
12. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci. 2002;7:d376-d389.
13. Pal SK, Figlin RA, Reckamp KL. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008;9:340-345.
14. Kozma SC, Thomas G: Regulation of cell size in growth, development and human disease: PI3 K, PKB and S6K. BioEssays. 2002;24:65-71.
15. Tang JM, He QY, Guo RX, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006;51:181-191.
16. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151-3171.
17. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4:658-665.
18. Wullschleger S, Loewith R, Hall MN. TOR Signaling in Growth and Metabolism. Cell. 2006;124:471-484.
19. Beugnet A, Tee AR, Taylor PM, et al. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J. 2003;372:555-566.
20. Houghton PJ. Everolimus. Clin Cancer Res. 16:1368-1372.
21. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296-313.
22. Grunwald V, DeGraffenried L, Russel D, et al. Inhibitors of mTOR Reverse Doxorubicin Resistance Conferred by PTEN Status in Prostate Cancer Cells. Cancer Res. 2002;62:6141-6145.
23. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical Correlates of mTOR Inhibition by the Rapamycin Ester CCI-779 and Tumor Growth Inhibition. Clinical Cancer Research. 2001;7:1758-1764.
24. Yu K, Toral-Barza L, Discafani C, et al. MTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8:249-258.
25. Raymond E, Alexandre J, Faivre S, et al. Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer. J Clin Oncol. 2004;22:2336-2347.
26. Fischer P, Patel P, Carducci MA, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. ASCO Meeting Abstracts 2008;26:16020.
27. Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol (Meeting Abstracts) 2007;25:5034.
28. Merchan JR, Pitot HC, Qin R, et al. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients. J Clin Oncol (Meeting Abstracts) 2009;27:5039.
29. NCT00631371: Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus) vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma (Available on-line at http://www.clinicaltrials.gov last accessed Dec 23, 2009).
30. Kim KB, Davies MA, Papadopoulos NE, et al. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. ASCO Meeting Abstracts 2009;27:9026.
31. NCT00378703: The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma [BeST]. Available at: http://www.clinicaltrials.gov Accessed Dec 22, 2009.
32. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma. J Clin Oncol. 2007;25:3958-3964.
33. Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). ASCO Meeting Abstracts 2006;24:LBA4.
34. Chang SM, Kuhn J, Lamborn K, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). ASCO Meeting Abstracts 2009;27:2004.
35. Carpenter JT, Roche H, Campone M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. ASCO Meeting Abstracts 2005;23:564.
36. National Comprehensive Cancer Network Clinical Practice Guidelines: Renal Cell Carcinoma (Available at http://www.nccn.org; last accessed Nov 29, 2009.).
37. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. N Engl J Med. 2003;349:847-858.
38. Cataneo-Davila A, Zuniga-Varga J, Correa-Rotter R, et al. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Transplant Proc. 2009;41:4138-4146.
39. O'Donnell A, Faivre S, Burris HA, III, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors. J Clin Oncol. 2008;26:1588-1595.
40. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data. J Clin Oncol. 2008;26:1596-1602.
41. Cen P, Daleiden A, Doshi G, et al. A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2009;27:e16056.
42. Kroog GS, Feldman DR, Kondagunta GV, et al. Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. ASCO Meeting Abstracts 2009;27:5037.
43. Zafar Y, Bendell J, Lager J, et al. Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. ASCO Meeting Abstracts 2006;24:3097.
44. NCT00719264: A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney. Available at: http://www.clinicaltrials.gov. Accessed Dec 22, 2009.
45. Chan JS, Vuky J, Besaw LA, et al. A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC). ASCO Meeting Abstracts 2007;25:15600.
46. Dumez H, Reichard P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinibresistant gastrointestinal stromal tumors (GIST). ASCO Meeting Abstracts 2008;26:10519.
47. Bendell JC, George D, Nixon A, et al. Results of a phase I study of bevacizumab (BV), everolimus (EV), and erlotinib (E) in patients with advanced solid tumors. ASCO Meeting Abstracts 2007;25:3548.
48. Howard LA, Bullock KE, Bendell JC, et al. Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors. ASCO Meeting Abstracts 2009;27:3551.
49. Andre F, Campone M, Hurvitz SA, et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. ASCO Meeting Abstracts 2008;26:1003.
50. Di Scala L, Pylvanainen I, Molloy B, et al. A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. ASCO Meeting Abstracts 2008;26:1130.
51. Hoban CJ, Hoering A, Synold TW, et al. Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528. ASCO Meeting Abstracts 2009;27:3553.
52. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. European Journal of Cancer. 2008;44:84-91.
53. Baselga J, Semiglazov V, van Dam P, et al. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2009;27:2630-2637.
54. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115:2438-2446.
55. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 2008;372:449-456.
56. Kay A, Motzer R, Figlin R, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). Presented at the 2009 Genitourinary Cancers Symposium [Abstr 278].
57. Brown NF, Stefanovic-Racic M, Sipula IJ, et al. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism. 2007;56:1500-1507.
58. Huffman TA, Mothe-Satney I, Lawrence JC Jr. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci U S A. 2002;99:1047-1052.
59. White DA, Camus P, Endo M, et al. Non-infectious Pneumonitis After Everolimus Therapy for Advanced Renal Cell Carcinoma. Am J Respir Crit Care Med.
60. Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology. 2008;19:1387-1392.
61. Rodriguez-Pascual J, Cheng E, Maroto P, et al. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anti-Cancer Drugs. 21:478-486 10.1097/CAD.0b013e32833760bf.
62. NCT00903175: Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-Line and Second-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (Available at http://www.ClinicalTrials.gov last accessed Jun 23, 2009).
63. Vickers MM, Choueiri TK, Zama I, et al. Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next? ASCO Meeting Abstracts 2009;27:5098.
64. Rini BI, Wilding G, Hudes G, et al. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009;27:4462-4468.
65. NCT00678392: Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer: Axis Trial (Available at http://www.clinicaltrials. gov; last accessed Decr 21, 2009).
66. NCT00474786: A Randomized Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy (Available on-line at http://www.clinicaltrials.gov last accessed Dec 21, 2009).
67. Wood L, Bukowski RM, Dreicer R, et al. Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy. ASCO Meeting Abstracts 2008;26:16067.
68. Dumont FJ, Staruch MJ, Grammer T, et al. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. Cell Immunol. 1995;163:70-79.
69. Chen J, Zheng XF, Brown EJ, et al. Identification of an 11-kDa FKBP12-rapamycinbinding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A. 1995;92:4947-4951.
70. Sugiyama H, Papst P, Fujita M, et al. Overexpression of wild type p70 S6 kinase interferes with cytokinesis. Oncogene. 1997;15:443-452.
71. Huang S, Houghton PJ: Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001;4:378-91.
72. Huang S, Houghton PJ. Resistance to rapamycin: a novel anticancer drug. Cancer Metastasis Rev. 2001;20:69-78.
73. Cho DC, Figlin RA, Flaherty KT, et al. A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). J Clin Oncol. (Meeting Abstracts) 2009;27:5101.
74. Vogelzang NJ, Hutson TE, Samlowski W, et al: Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. J Clin Oncol (Meeting Abstracts) 2009;27:5034.
75. NCT01049841: Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors (Available at http://www.clinicaltrials.gov last accessed Apr 10, 2010.).
76. Gordan JD, Lal P, Dondeti VR, et al. HIF-[alpha] Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma. Cancer Cell. 2008;14:435-446.